THE COMPANY
Building the next generation of personalized immunotherapy
Odimma Therapeutics is a biotechnology company developing precision immunotherapy approaches designed around the biology of each individual patient.
The company started around the vision that the future of immunotherapy lies in personalized therapeutic design — integrating biology, data and synthetic engineering into clinically actionable approaches.
Every patient carries
a different biological story.
Precision medicine should respond to it.
Integrating biology, AI and synthetic DNA engineering into personalized therapeutic development
A platform-driven biotechnology company
————
Odimma Therapeutics is developing a precision immunotherapy platform designed to support personalized therapeutic strategies across multiple clinical settings.
The company’s initial clinical focus is oncology, with ODI-2001 representing the first therapeutic program emerging from the platform.
Leadership
___
Odimma Therapeutics brings together expertise across oncology, immunology,
pharmaceutical development, regulatory strategy and personalized medicine.
Jean-Marc Limacher, MD
Chairman, Co-Founder, CMO
Medical Oncologist & Cancer Geneticist
Jean-Marc Limacher is a medical oncologist and cancer geneticist. He began his career at the University Hospitals of Strasbourg, where he established the institution’s cancer family clinic dedicated to hereditary cancer management.
In 2004, he joined Transgene as Medical Director, where he led the clinical development of several cancer immunotherapy programs. His work in oncology and immunotherapy has contributed to more than 60 scientific publications.
In 2016, he filed a patent application for an innovative personalised immunotherapy platform, which led to the co-founding of Odimma Therapeutics in 2017. He currently serves as Chairman and Chief Medical Officer of Odimma Therapeutics.
Scientific & Pharmaceutical Development Team
———
Jérémy Amzallag
———
PharmD, Qualified Person
Ronald Rooke, PhD
———
Scientific Affairs, Immunology and Oncology
Pascale Balducchi
———
Partner Consultant – Strategy & Business
Delphine Courade
———
Clinical Supply Management
Rémi Gloeckler, PhD
———
Partner – Pharmaceutical Development – Biologist
Célia Matta, PhD
———
Preclinical Research & Development, Laboratory operations
Nicolas Ferry, MD, PhD
———
Regulatory Affairs
Former biologics director at ANSM and former EMA CAT member
Margaux Longuespée, PhD
———
Pharmaceutical Quality
Strategic Board
———
Jean-Marc Limacher, MD
———
Jean-Yves Bonnefoy, PhD
———
Patrick Squiban, MD
———
Peter de Waele, PhD
———
Virginia Math
———
our partners
——————————————————
Built Through
Strategic Partnerships
Odimma Therapeutics collaborates with leading biotechnology, genomic sequencing, manufacturing and clinical organizations to support the development of scalable personalized immunotherapy platforms.
TECHNOLOGY & MANUFACTURING partners
————————————————————————————————————————————————————
Synthetic DNA Manufacturing
Neoantigen Prediction
Tumor Sequencing
MVA Viral Component
ECOSYSTEM & INNOVATION SUPPORT
————————————————————————————————————————————————————
Supported by a growing network of institutional partners across Europe.
Designed for the future
of personalized therapeutics.
THE COMPANY
Building the next generation of personalized immunotherapy
Odimma Therapeutics is a biotechnology company developing precision immunotherapy approaches designed around the biology of each individual patient.
The company started around the vision that the future of immunotherapy lies in personalized therapeutic design — integrating biology, data and synthetic engineering into clinically actionable approaches.
Every patient carries
a different biological story.
Precision medicine should respond to it.
Integrating biology, AI and synthetic DNA engineering into personalized therapeutic development
A platform-driven biotechnology company
Odimma Therapeutics is developing a precision immunotherapy platform designed to support personalized therapeutic strategies across multiple clinical settings.
The company’s initial clinical focus is oncology, with ODI-2001 representing the first therapeutic program emerging from the platform.
Leadership
___
Odimma Therapeutics brings together expertise across oncology, immunology, pharmaceutical development, regulatory strategy and personalized medicine.
Jean-Marc Limacher, MD
Chairman, Co-Founder, CMO
Medical Oncologist & Cancer Geneticist
Jean-Marc Limacher is a medical oncologist and cancer geneticist. He began his career at the University Hospitals of Strasbourg, where he established the institution’s cancer family clinic dedicated to hereditary cancer management.
In 2004, he joined Transgene as Medical Director, where he led the clinical development of several cancer immunotherapy programs. His work in oncology and immunotherapy has contributed to more than 60 scientific publications.
In 2016, he filed a patent application for an innovative personalised immunotherapy platform, which led to the co-founding of Odimma Therapeutics in 2017. He currently serves as Chairman and Chief Medical Officer of Odimma Therapeutics.
Scientific & Pharmaceutical Development Team
———
Jérémy Amzallag
———
PharmD, Qualified Person
Ronald Rooke, PhD
———
Scientific Affairs, Immunology and Oncology
Pascale Balducchi
———
Partner Consultant – Strategy & Business
Delphine Courade
———
Clinical Supply Management
Rémi Gloeckler, PhD
———
Partner – Pharmaceutical Development – Biologist
Célia Matta, PhD
———
Preclinical Research & Development, Laboratory operations
Nicolas Ferry, MD, PhD
———
Regulatory Affairs
Former biologics director at ANSM and former EMA CAT member
Margaux Longuespée, PhD
———
Pharmaceutical Quality
Strategic Board
———
Jean-Marc Limacher, MD
———
Jean-Yves Bonnefoy, PhD
———
Patrick Squiban, MD
———
Peter de Waele, PhD
———
Virginia Math
———
our partners
—————————————————
Built Through
Strategic Partnerships
Odimma Therapeutics collaborates with leading biotechnology, genomic sequencing, manufacturing and clinical organizations to support the development of scalable personalized immunotherapy platforms.
TECHNOLOGY & MANUFACTURING partners
——————————————————
Synthetic DNA Manufacturing
Neoantigen
Prediction
Tumor
Sequencing
MVA Viral Component
ECOSYSTEM
& INNOVATION SUPPORT
—————————————————
Supported by a growing network of institutional partners across Europe.